SJS Investment Consulting’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$86K Buy
681
+2
+0.3% +$264 0.01% 271
2026
Q1
$94.6K Buy
679
+311
+85% +$43.6K 0.01% 222
2025
Q4
$45.2K Sell
368
-124
-25% -$15.1K 0.01% 395
2025
Q3
$54.6K Buy
492
+335
+213% +$38.1K 0.01% 250
2025
Q2
$17.4K Sell
157
-635
-80% -$67.6K ﹤0.01% 293
2025
Q1
$88.7K Buy
792
+4
+0.5% +$413 0.02% 148
2024
Q4
$72.8K Buy
788
+573
+267% +$51.6K 0.01% 160
2024
Q3
$18K Buy
215
+4
+2% +$305 ﹤0.01% 293
2024
Q2
$14.5K Sell
211
-17
-7% -$1.13K ﹤0.01% 301
2024
Q1
$16.7K Buy
228
+93
+69% +$7.15K ﹤0.01% 301
2023
Q4
$10.9K Sell
135
-22
-14% -$1.71K ﹤0.01% 288
2023
Q3
$11.8K Buy
157
+39
+33% +$3K ﹤0.01% 273
2023
Q2
$9.1K Sell
118
-285
-71% -$22.7K ﹤0.01% 281
2023
Q1
$33.4K Buy
403
+263
+188% +$21.8K 0.01% 177
2022
Q4
$12K Buy
140
+42
+43% +$3.33K ﹤0.01% 269
2022
Q3
$6K Buy
+98
New +$6.18K ﹤0.01% 320
2022
Q1
$3K Buy
62
+29
+88% +$1.85K ﹤0.01% 478
2021
Q4
$2K Buy
+33
New +$2.27K ﹤0.01% 472

Other funds holding GILD

SJS Investment Consulting's GILD Position: Q2 2026 in Review

SJS Investment Consulting increased its Gilead Sciences (GILD) stake by 0.29% in Q2 2026, buying an estimated $264 and bringing the position to 681 shares worth $86K. The position accounts for 0.01% of the portfolio, ranked #271.

SJS Investment Consulting first reported a position in GILD in Q4 2021 and has held it in 18 quarters since. The position peaked at $94.6K in Q1 2026. 853 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • SJS Investment Consulting held 681 shares of Gilead Sciences worth $86K as of Q2 2026.
  • SJS Investment Consulting bought 2 Gilead Sciences shares in Q2 2026, an estimated $264.
  • Gilead Sciences made up 0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #271 holding.
  • SJS Investment Consulting first reported a position in Gilead Sciences in Q4 2021 and has held it in 18 quarters since.
  • SJS Investment Consulting's Gilead Sciences position peaked at $94.6K in Q1 2026.
  • 853 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.